Spotlight on fondaparinux sodium in acute coronary syndromes

BioDrugs

Volumn 22, Issue 6, 2008, Pages 413-415

  Blick, Stephanie K A ^a,b   Orman, Jennifer S ^a,b   Wagstaff, Antona J ^a,b   Scott, Lesley J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug profiles; Coronary disorders; Fondaparinux sodium, general

Indexed keywords

ENOXAPARIN; FONDAPARINUX;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOTTING TIME; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; HUMANS; POLYSACCHARIDES; TREATMENT OUTCOME;

EID: 56049105890     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/0063030-200822060-00007     Document Type: Short Survey

References (15)

1. Blick SKA, Orman JS, Wagstaff AJ, et al. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Am J Cardiovasc Drugs 2008; 8 (2): 113-25
2. Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentassarcharide. J Med Chem 1997; 40: 1600-7
3. Lormeau JC, Herault JP, Gaich C, et al. Determination of the antifactor Xa activity of the synthetic pentasaccharide SR 9017A/ORG 31540 and of two structural analogues. Thromb Res 1997; 85 (1): 67-75
4. Bauer KA. New pentassaccharides for prophylaxis of deep vein thrombosis. Chest 2003; 124 (6): 364S-70S
5. Olson ST, Bjork I, Sheffert R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin proteinase reactions. J Biol Chem 1992 Jun; 267 (18): 12528-38
6. Robinson DM, Wellington K. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. Am J Cardiovasc Drugs 2005; 5 (5): 335-46
7. European Medicines Agency. Fondaparinux sodium: Arixtra™ 1.5mg/0.3mL solution for injection; summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/arixtra/H- 403-PI-en.pdf [Accessed 2008 Mar 28]
8. Boneu B, Necciari J, Cariou R, et al. Pharmacokinteics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74 (6): 1468-73
9. Bijsterveld MD, Moons AH, Boekholdt M, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002 Nov 12; 106: 2550-4
10. US Food and Drug Administration. Fondaparinux Sodium: Atrixtra® injection prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/021354s010LbL.pdf [Accessed 2008 Mar 28]
11. Donat F, Duret JP, Santoni A. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 1-9
12. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006 Apr 6; 354 (14): 1464-76
13. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006 Apr 5; 295 (13): 1519-30
14. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007 Oct 30; 50 (18): 1742-51
15. Genth-Zotz S, Rupprecht H-J, Mehta SR, et al. Early benefit of fondaparinux in patients with non-ST elevation acute coronary syndromes: a secondary analysis of the OASIS-5 trial [abstract no. V1744]. 73rd Annual Meeting of the German Society for Cardiology, Heart and Circulation Research; 2007 Apr 12-14; Mannheim